(Q35644910)

9 August 2017

title

Experimental autoimmune myasthenia gravis in the mouse. (English)

1 reference

9 August 2017

0 references

B Wu

1

1 reference

9 August 2017

E Goluszko

series ordinal

2

1 reference

9 August 2017

P Christadoss

series ordinal

3

1 reference

9 August 2017

publication date

1 May 2001

1 reference

Current Protocols in Immunology

9 August 2017

published in

1 reference

9 August 2017

volume

Chapter 15

1 reference

9 August 2017

page(s)

Unit 15.8

1 reference

Targeting classical complement pathway to treat complement mediated autoimmune diseases

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

Animal models of myasthenia gravis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

12 July 2018

Affinity chromatography

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

Immunogenetics of experimental autoimmune myasthenia gravis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

Etanercept treatment in corticosteroid-dependent myasthenia gravis

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

Genetic Evidence for Involvement of Classical Complement Pathway in Induction of Experimental Autoimmune Myasthenia Gravis

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

Role of IL-5 during primary and secondary immune response to acetylcholine receptor

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

Isolation of the Principal Neurotoxins of Two Naja naja Subspecies

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249402

Autoimmune human T lymphocytes specific for acetylcholine receptor

25 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2F0471142735.IM1508S21

HLA-DQ beta-chain polymorphism linked to myasthenia gravis

21 January 2018

1 reference

12 December 2020

Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal anti-idiotopic antibody

1 reference

12 December 2020

Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis

1 reference

12 December 2020

Suppression of Experimental Autoimmune Myasthenia Gravis by Epitope-Specific Neonatal Tolerance to Synthetic Region α146-162 of Acetylcholine Receptor

1 reference

12 December 2020

T-cell receptor gene usage of acetylcholine receptor-specific T-helper cells

1 reference

12 December 2020

Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis

1 reference

12 December 2020

1 reference

12 December 2020

The pathogenic role of acetylcholine receptor alpha chain epitope within alpha 146-162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice

1 reference

12 December 2020

Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis

1 reference

12 December 2020

TCR gene usage in experimental autoimmune myasthenia gravis pathogenesis. Usage of multiple TCRBV genes in the H-2b strains

1 reference

12 December 2020

IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis

1 reference

12 December 2020

Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors

1 reference

12 December 2020

IFN-alpha therapy is effective in suppressing the clinical experimental myasthenia gravis.

1 reference

12 December 2020

1 reference

12 December 2020

29 Production and assay of antibodies to acetylcholine receptors

1 reference

12 December 2020

Immunotherapy for myasthenia gravis: a murine model

1 reference

12 December 2020

Immune response gene control of lymphocyte proliferation induced by acetylcholine receptor-specific helper factor derived from lymphocytes of myasthenic mice

1 reference

12 December 2020

10.1002/0471142735.IM1508S21

Identifiers

DOI

1 reference

9 August 2017

1 reference

9 August 2017

1 reference